`
`Not for Publication
`
`
`
`Civil Action No. 13-0391 (ES) (JAD)
`
`UNITED STATES DISTRICT COURT
`DISTRICT OF NEW JERSEY
`
`
`
`
`
`
`
`
`
`:
`
`
`
`
`
`
`JAZZ PHARMACEUTICALS, INC.,
`:
`
`and JAZZ PHARMACEUTICALS
`:
`IRELAND LIMITED,
`
`
`:
`
`
`
`
`
`
`:
`Plaintiffs,
`
`
`:
`
`
`
`
`:
`v.
`
`
`
`:
`
`
`
`
`:
`
`
`AMNEAL PHARMACEUTICALS,
`:
`LLC, et al.,
`
`
`
`
`:
`
`
`
`
`
`
`:
`Defendants.
`
`
`:
`:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`ORDER
`
`
`
`SALAS, DISTRICT JUDGE
`
`
`
`After considering the parties’ submissions and hearing oral argument on the matter; and
`
`
`
`for the reasons stated in the Court’s accompanying Opinion;
`
`
`
`
`
`IT IS on this 6th day of November 2017;
`
`ORDERED that the following disputed claim terms of the patents identified in the
`
`accompanying Opinion shall be construed as follows:
`
`1. “Third container means” is a means-plus-function term under 35 U.S.C. § 112, ¶ 6 and is
`indefinite under § 112, ¶ 2.
`
`2. “The components are admixed sequentially” and “the components are admixed
`simultaneously” are construed in accordance with their plain and ordinary meaning.
`
`3. “Administering” is construed in accordance with its plain and ordinary meaning.
`
`4. “Currently taking” is construed in accordance with its plain and ordinary meaning.
`
`
`s/Esther Salas
`Esther Salas, U.S.D.J.
`
`
`
`
`
`